BVX-001

DB18733ExperimentalProtein Based Therapies

BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.

Mechanism: Pharmacologically active on Myeloid cell surface antigen CD33 and T-cell antigen CD7
Curator reviewed
Code names: BVX-001

Resolves to

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with BVX-001, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.